Korean J Hematol.  2012 Mar;47(1):28-38. 10.5045/kjh.2012.47.1.28.

Statistics of hematologic malignancies in Korea: incidence, prevalence and survival rates from 1999 to 2008

• Park HJ
• Park EH
• Jung KW
• Kong HJ
• Won YJ
• Lee JY
• Yoon JH
• Park BK
• Lee H
• Eom HS
• Park S

• KMID: 2251968
• DOI: http://doi.org/10.5045/kjh.2012.47.1.28

Abstract

BACKGROUND
The nationwide statistical analysis of hematologic malignancies in Korea has not been reported yet.
METHODS
The Korea Central Cancer Registry and the Korean Society of Hematology jointly investigated domestic incidence rates and prevalence of hematologic malignancies occurred between 1999 and 2008, and analyzed survival rates of patients who were diagnosed between 1993 and 2008. Data of hematologic malignancies from 1993 to 2008 were obtained from the Korean National Cancer Incidence Data base. The crude incidence rates, age-specific incidence rates, age-standardized incidence rates, annual percentage change of incidence, and prevalence from 1999-2008 were calculated. Survival rates for patients diagnosed in 1993-2008 were estimated.
RESULTS
In 2008, a total of 8,006 cases of hematologic malignancies were occurred, which comprised 4.5% of all malignancies. In all genders, non-Hodgkin lymphoma, myeloid leukemia, and multiple myeloma were most frequent diseases. In terms of age, ages between 60 and 69 were most prevalent. From 1999 to 2008, the age-standardized incidence rates increased from 10.2 to 13.7, and the annual percentage change was 3.9%. The 5-year survival rate increased from 38.2% during 1993-1995 to 55.2% during 2004-2008. As of January 2009, number of patients with 10-year prevalence was 33,130, and with 5- to 10-year prevalence was 10,515.
CONCLUSION
This is the first nationwide statistical report of hematologic malignancies in Korea. It could be used as the basic information to help investigate epidemiologic characteristics, evaluate progress during the past years, and establish future strategies for hematologic malignancies. Periodic statistical analysis of hematologic malignancies in Korea should be continued.

Keyword

Hematologic malignancy; Incidence; Survival; Prevalence; Korea

MeSH Terms

Hematologic Neoplasms
Hematology
Humans
Incidence
Korea
Leukemia, Myeloid
Lymphoma, Non-Hodgkin
Multiple Myeloma
Prevalence
Survival Rate

Figure

• 

  Fig. 1 Relative frequency of hematologic malignancies in Korea, 2008. (A) Men. (B) Women.

• 

  Fig. 2 Incident cases of hematologic malignancies by age group in Korea, 2008.

• 

  Fig. 3 Age-specific incidence rates of hematologic malignancies in Korea, 2008. (A) Men. (B) Women.

• 

  Fig. 4 Five-year survival rate of hematologic malignancies from 1993 to 2008 in Korea. a)Official registration employing ICD-O-3 began in 2003 at KCCR.

• 

  Fig. 5 Number of prevalent cases of hematologic malignancies by time since diagnosis in January 1, 2009 in Korea. a)Because official registration for MPD and MDS began in 2003, 5-10 year prevalence cases for these cancers are underestimated.

Reference

1. Storm HH, Klint A, Tryggvadóttir L, et al. Trends in the survival of patients diagnosed with malignant neoplasms of lymphoid, haematopoietic, and related tissue in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol. 2010. 49:694–712.

2. Pulte D, Gondos A, Brenner H. Trends in survival after diagnosis with hematologic malignancy in adolescence or young adulthood in the United States, 1981-2005. Cancer. 2009. 115:4973–4979.

3. Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010. 116:3724–3734.

4. Marcos-Gragera R, Allemani C, Tereanu C, et al. Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project. Haematologica. 2011. 96:720–728.

5. Morton LM, Turner JJ, Cerhan JR, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007. 110:695–708.

6. Ministry of Health and Welfare. The Korea central cancer registry. Annual report of cancer statistics in Korea in 2008. 2010. Seoul, Korea: Ministry of Health and Welfare.

7. Fritz A, Percy C, Jack A, editors. International classification of diseases for oncology. 2000. 3rd ed. Geneva, Switzerland: World Health Organization.

8. World Health Organization. International statistical classification of diseases and related health problems (ICD-10) in occupational health. 1999. Geneva, Switzerland: World Health Organization.

9. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000. 19:335–351.

10. Lee ET, Wang JW, editors. Statistical methods for survival data analysis. 2003. 3rd ed. Hoboken, NJ: John Wiley & Sons Inc.

11. SEER*Stat software program, version 7.0.5. National Cancer Institute. 2011. Accessed February 7, 2012. Bethsda, MD: National Cancer Institute;at http://seer.cancer.gov/seerstat/.

12. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2. Cancer incidence, mortality and prevalence worldwide in 2008. IARC CancerBase No. 10. 2010. Accessed December 1, 2011. Lyon, France: International Agency for Research on Cancer;at http://globocan.iarc.fr/.

13. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008. 112:45–52.

14. Mester B, Nieters A, Deeg E, Elsner G, Becker N, Seidler A. Occupation and malignant lymphoma: a population based case control study in Germany. Occup Environ Med. 2006. 63:17–26.

15. Eden T. Aetiology of childhood leukaemia. Cancer Treat Rev. 2010. 36:286–297.

16. Alexander FE. The search for causes of the leukaemias. Eur J Cancer. 1995. 31A:863–867.

17. Bezabeh S, Engel A, Morris CB, Lamm SH. Does benzene cause multiple myeloma? An analysis of the published case-control literature. Environ Health Perspect. 1996. 104:Suppl 6. 1393–1398.

18. Alexander DD, Mink PJ, Adami HO, et al. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer. 2007. 120:Suppl 12. 1–39.

19. Gorini G, Stagnaro E, Fontana V, et al. Alcohol consumption and risk of leukemia: a multicenter case-control study. Leuk Res. 2007. 31:379–386.

20. Cook MB, Dawsey SM, Freedman ND, et al. Sex disparities in cancer incidence by period and age. Cancer Epidemiol Biomarkers Prev. 2009. 18:1174–1182.

21. Sankaranarayanan R, Swaminathan R, Jayant K, Brenner H. An overview of cancer survival in Africa, Asia, the Caribbean and Central America: the case for investment in cancer health services. IARC Sci Publ. 2011. 162:257–291.

22. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2008. 2011. Accessed December 1, 2011. Bethesda, MD: National Cancer Institute;at http://seer.cancer.gov/statfacts/html/all.html.

23. Jung KW, Park S, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008. Cancer Res Treat. 2011. 43:1–11.

24. Howell D, Hack TF, Oliver TK, et al. Survivorship services for adult cancer populations: a pan-Canadian guideline. Curr Oncol. 2011. 18:e265–e281.